RZLT
RZLT clinical trials: Rezolute, Inc.
Every trial on ClinicalTrials.gov where Rezolute, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 5
- Trials linked
- 5
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
RZLT on the catalyst calendar · RZLT registry changes
- Primary completion Not registeredNo phase registeredNCT07262970Intermediate-Size Cohort EAP for Ersodetug in Patients With Inadequately Controlled Hypoglycemia Related to a TumorRezolute · Tumor-associated Hyperinsulinism (Tumor HI)AvailableRZLTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2027Sponsor estimatePhase 3NCT06881992A Phase 3 Study of Ersodetug in Patients With Tumor HyperinsulinismRezolute · Tumor Hyperinsulinism (Tumor HI)RecruitingRZLTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 11, 2024ActualPhase 2NCT05712720Study to Evaluate the Efficacy and Safety of RZ402 in Diabetic Macular Edema (DME)Rezolute · Diabetic Macular EdemaCompletedRZLTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 14, 2025ActualPhase 3NCT06208215RZ358 Treatment for Congenital HyperinsulinismRezolute · Congenital HyperinsulinismActive, not recruitingRZLTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 5, 2022ActualPhase 2NCT04538989An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital HyperinsulinismRezolute · Congenital HyperinsulinismCompletedRZLTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 5 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner